{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:57:50Z","timestamp":1791568670807,"version":"4.3.4"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To assess efficacy and safety of a single-dose vaginal clindamycin gel for bacterial vaginosis treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>We conducted a double-blind, placebo-controlled, randomized study comparing clindamycin gel with placebo (2:1 ratio). Entry required clinical diagnosis of bacterial vaginosis, that is, all four Amsel's criteria, without other genital infections. Nugent scores of 7\u201310 were required for efficacy assessment, per updated 2019 U.S. Food and Drug Administration guidance. Patients were evaluated at screening, day 7\u201314, and day 21\u201330 (test of cure). <jats:italic toggle=\"yes\">Clinical cure<\/jats:italic> was defined as resolution of three of four Amsel's criteria. <jats:italic toggle=\"yes\">Bacteriologic cure<\/jats:italic> was defined as Nugent score lower than 4. Therapeutic cure was both clinical and bacteriologic cure. Primary outcome was clinical cure at the test-of-cure visit. Secondary endpoints were clinical cure at day 7\u201314, and bacteriologic and therapeutic cures at day 7\u201314 and test of cure. A sample size of 188 patients in the clindamycin group compared with 94 patients in the placebo group had 90% power to detect statistically significant difference (<jats:italic toggle=\"yes\">P<\/jats:italic>=.05, 2-tailed).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Participants were seen between July 9, 2020, and November 12, 2020. Of 307 randomized women, 56.0% were Black and 88.3% reported one or more previous bacterial vaginosis episodes. In the modified intention-to-treat population, 70.5% of patients in the clindamycin group and 35.6% in the placebo group achieved clinical cure at test of cure (primary outcome) (difference of 34.9, 95% CI 19.0\u201350.8), as did 77.5% of patients in the clindamycin group and 42.6% of patients in the placebo group in the per-protocol population (difference of 34.9, 95% CI 17.0\u201352.7). Statistically significant differences between groups were seen for all secondary endpoints. Clinical cure rate in patients in the clindamycin group with more than three bacterial vaginosis episodes in the prior year was 70.0%. Approximately 15% (15.3%) of patients in the clindamycin group experienced one or more treatment-emergent adverse events related to study treatment, as did 9.7% of patients in the placebo group. The most frequent treatment-related, treatment-emergent adverse event was vulvovaginal candidiasis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>A new, single-dose clindamycin vaginal gel was highly effective, with excellent safety, in women disproportionately affected by bacterial vaginosis, with Nugent scores of 7\u201310 at study entry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>FUNDING SOURCE:<\/jats:title>\n            <jats:p>The study was funded by Dar\u00e9 Bioscience, Inc.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL TRIALS REGISTRATION:<\/jats:title>\n            <jats:p>\n                                 ClinicalTrials.gov, NCT04370548.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000004805","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T11:00:13Z","timestamp":1654167613000},"page":"1092-1102","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Single-Dose, Bioadhesive Clindamycin 2% Gel for Bacterial Vaginosis"],"prefix":"10.1097","volume":"139","author":[{"given":"Christine","family":"Mauck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Hillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Gendreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint","family":"Dart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Chavoustie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Sorkin-Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifton","family":"Nicholson-Uhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadene","family":"Zack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Friend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"R1-20250423","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ajog.2020.10.019","article-title":"Bacterial vaginosis and its association with infertility, endometritis, and pelvic inflammatory disease","volume":"224","author":"Ravel","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"R2-20250423","doi-asserted-by":"crossref","first-page":"e00342","DOI":"10.1128\/JCM.00342-18","article-title":"Molecular diagnosis of bacterial vaginosis: an update","volume":"56","author":"Coleman","year":"2018","journal-title":"J Clin Microbiol"},{"key":"R3-20250423","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/OLQ.0b013e318074e565","article-title":"The prevalence of bacterial vaginosis in the United States, 2001\u20132004; associations with symptoms, sexual behaviors, and reproductive health","volume":"34","author":"Koumans","year":"2007","journal-title":"Sex Transm Dis"},{"key":"R5-20250423","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/jcm.29.2.297-301.1991","article-title":"Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation","volume":"29","author":"Nugent","year":"1991","journal-title":"J Clin Microbiol"},{"key":"R6-20250423","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0002-9343(83)91112-9","article-title":"Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations","volume":"74","author":"Amsel","year":"1983","journal-title":"Am J Med"},{"key":"R7-20250423","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1128\/JCM.01272-07","article-title":"Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis","volume":"45","author":"Fredricks","year":"2007","journal-title":"J Clin Microbiol"},{"key":"R8-20250423","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3109\/03639045.2011.555913","article-title":"Evaluation of TRI-726 as a drug delivery matrix","volume":"37","author":"Mondal","year":"2011","journal-title":"Drug Dev Ind Pharm"},{"issue":"suppl 3","key":"R10-20250423","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1086\/321854","article-title":"Does the dose matter?","volume":"33","author":"Craig","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R11-20250423","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1128\/AAC.40.8.1941","article-title":"Characterization of bactericidal activity of clindamycin against Bacteroides fragilis via kill curve methods","volume":"40","author":"Klepser","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-20250423","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1007\/s00134-004-2428-9","article-title":"Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness","volume":"30","author":"Mehrotra","year":"2004","journal-title":"Intensive Care Med"},{"key":"R13-20250423","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/jps.2600620410","article-title":"Clindamycin dose-bioavailability relationships","volume":"62","author":"Metzler","year":"1973","journal-title":"J Pharm Sci"},{"key":"R14-20250423","first-page":"701","article-title":"Clindamycin (Cleocin) in bacterial pneumonia","volume":"12","author":"Quintiliani","year":"1970","journal-title":"Curr Ther Res Clin Exp"},{"key":"R15-20250423","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1517\/14656566.2014.881800","article-title":"Treatment of bacterial vaginosis: what we have and what we miss","volume":"15","author":"Donders","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"R16-20250423","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.contraception.2006.09.003","article-title":"Fourteen-day safety and acceptability study of the universal placebo gel","volume":"75","author":"Schwartz","year":"2007","journal-title":"Contraception"},{"key":"R18-20250423","doi-asserted-by":"crossref","first-page":"e01643-19","DOI":"10.1128\/JCM.01643-19","article-title":"Clinical validation of the aptima bacterial vaginosis and aptima Candida\/Trichomonas vaginitis assays: results from a prospective multicenter clinical study","volume":"58","author":"Schwebke","year":"2020","journal-title":"J Clin Microbiol"},{"key":"R19-20250423","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/AOG.0b013e3181909f63","article-title":"Accuracy of the clinical diagnosis of vaginitis compared with a DNA probe laboratory standard","volume":"113","author":"Lowe","year":"2009","journal-title":"Obstet Gynecol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:02:27Z","timestamp":1745434947000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004805"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004805","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,2]]},"assertion":[{"value":"2021-12-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}